Revolutionizing Cancer Immunotherapy
While immune checkpoint inhibitors have transformed cancer treatment, only 50% of patients fail to respond, with resistance being a major challenge, particularly in aggressive cancers such as triple-negative breast cancer (TNBC). TNBC accounts for 15–20% of breast cancer cases and is often diagnosed at advanced stages, with current therapies offering limited efficacy.

Breakthrough Discovery: Galectin 3 and Immune Evasion
Our research has uncovered a tumor escape mechanism driven by Galectin 3, a protein linked to poor prognosis. Galectin 3 suppresses immune function by binding to CD45 on immune cells, preventing effective anti-tumor responses.

Our Solution: Restoring Immune Activation
We have developed proprietary immune-modulating peptides that target a unique CD45 epitope, disrupting the Galectin 3–CD45 interaction. This novel approach:
✔ Reverses immune suppression and restores T-cell activation.
✔ Enhances tumor-specific immune responses and improves efficacy of existing therapies.
✔ Provides a complementary mechanism of action to immune checkpoint inhibitors, increasing treatment success.

Advantages & Competitive Edge
• Overcomes immunotherapy resistance in hard-to-treat tumors.
• Low toxicity profile with minimal immune-related adverse effects.
• Easily produced and cost-effective, with minimal drug-drug interactions.
• Compatible with current immunotherapies, offering synergistic potential.